Table 2.

Completed, ongoing, and planned studies of rivipansel, SelG1, regadenoson, and NKTT120

Completed, ongoing, and planned studies of rivipansel, SelG1, regadenoson, and NKTT120
Completed, ongoing, and planned studies of rivipansel, SelG1, regadenoson, and NKTT120

RCT indicates randomized controlled trial; and SAE, serious adverse event.

* Dose schedule noted for dose-seeking studies is final dose achieved.

† The first 31 subjects received a 20 mg/kg loading dose and then 10 mg/kg every 12 hours.

‡ Adult dose listed in table. Pediatric dose will be 40 mg/kg load followed by 20 mg/kg every 12 hours up to 15 doses.

Close Modal

or Create an Account

Close Modal
Close Modal